Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Relative Risk

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Blood·2026

Same author

Heat exhaustion, domestic heat exposure and socioeconomic disparities among older adults: a cross-sectional mediation analysis from Germany.

International journal for equity in health·2026

Same author

Retroperitoneal bulk predicts chylothorax in follicular lymphoma-control requires systemic response.

Leukemia·2026

Same author

Bridging two worlds: harmonizing pediatric and adult ALL.

Blood advances·2026

Same author

Posture dependent changes in perceptual threshold during light touch foot sole stimulation.

Somatosensory & motor research·2026

Same author

Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers.

Blood cancer journal·2026

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Curtis A Lachowiez¹, Joshua F Zeidner², Jad Othman^3,4,5

¹Oregon Health and Science University, Portland, OR.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology

|July 2, 2026

Summary

This summary is machine-generated.

A new Prognostic Risk Integration for Survival Modeling (PRISM) score accurately predicts survival for acute myeloid leukemia (AML) patients on venetoclax-based therapy. This tool improves risk stratification beyond current methods for personalized treatment decisions.

Related Experiment Videos

Last Updated: Jul 4, 2026

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Area of Science:

Hematology
Oncology
Genomics

Background:

Risk stratification for acute myeloid leukemia (AML) patients receiving lower-intensity venetoclax-based therapy is currently suboptimal.
There is a need for improved prognostic models that integrate diverse patient data.

Purpose of the Study:

To develop and validate a prognostic model, the Prognostic Risk Integration for Survival Modeling (PRISM) score, for AML patients treated with hypomethylating agents plus venetoclax (HMA + VEN).
To integrate clinical, cytogenetic, and molecular features for enhanced survival risk stratification.

Main Methods:

A multinational dataset of 2,092 adults with newly diagnosed AML treated with HMA + VEN was assembled.
Elastic Net and Ridge regression were used to develop the PRISM score, which was validated in internal and external cohorts.
The PRISM score was compared against the existing 4-gene classifier.

Main Results:

The PRISM model integrated 17 clinical and genomic variables and showed a linear association with overall survival (OS).
PRISM-3 risk categories (low, moderate, high) consistently stratified survival across all validation cohorts (P < .001).
PRISM-3 demonstrated significantly better discrimination than the 4-gene classifier in validation cohorts (C-index 0.63-0.65 vs. 0.59-0.61; P < .05).

Conclusions:

PRISM is a validated prognostic model that enhances survival risk stratification for AML patients on HMA + VEN therapy.
The PRISM score supports individualized, risk-adapted clinical decision-making.
The PRISM model is publicly accessible at prism-aml.com for clinical use.